Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group.
Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis.
L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients.
Primary progressive multiple sclerosis-why we are failing.
Prevention and Mitigation of Experimental Autoimmune Encephalomyelitis by Murine β-Defensins via Induction of Regulatory T Cells.
Risk alleles for multiple sclerosis identified by a genomewide study.
Brief International Cognitive Assessment for MS (BICAMS): international standards for validation.
Brain MRI results of DECIDE: a randomized, double-blind trial of DAC HYP vs. IFNβ-1a in RRMS patients
A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis.
Fumaric Acid Esters Do Not Reduce Inflammatory NF-κB/p65 Nuclear Translocation, ICAM-1 Expression and T-Cell Adhesiveness of Human Brain Microvascular Endothelial Cells.
INF-β1b therapy modulates L-arginine and nitric oxide metabolism in patients with relapse remittent multiple sclerosis.
Differential effects of interferon-β1b on cytokine patterns of CD4+ and CD8+ T cells derived from RRMS and PPMS patients.
IFN-β Treatment Requires B Cells for Efficacy in Neuroautoimmunity.
Phase III study: Ocrelizumab significantly reduces disease activity in PPMS patients
The complex role of estrogens in inflammation.
The Oxford English Corpus: Facts about the language, The Story of Dictionaries
Mycophenolate mofetil in multiple sclerosis: a multicentre retrospective study on 344 patients.
An RNA profile identifies two subsets of multiple sclerosis patients differing in disease activity.
Safety Study of Combination Therapy with Intramuscular Avonex and Oral CellCept in Patients with Multiple Sclerosis
Structure of the LINGO-1-anti-LINGO-1 Li81 antibody complex provides insights into the biology of LINGO-1 and the mechanism of action of the antibody therapy.
Biogen Idec and Genentech announce restructuring of anti-CD20 collaboration agreement
Comparative pharmacogenetics of multiple sclerosis: IFN-β versus glatiramer acetate.
Suppression of CD4+ T cell activation by a novel inhibitor of Src family kinases.
Spontaneous relapsing-remitting EAE in the SJL/J mouse: MOG-reactive transgenic T cells recruit endogenous MOG-specific B cells.
Estriol preserves synaptic transmission in the hippocampus during autoimmune demyelinating disease.

Pages